Benefits
- A multi-strain blend which approximates the normal composition of intestinal flora and ensures balance to the entire intestinal tract
- Provides 8 human origin strains, 3 dairy, and 1 vegetable origin strain
- Each strain has specific inhibitive functions against pathogenic and putrefactive microorganisms throughout the entire GI tract
- Each strain is resistant to gastric acidity as well as high-bile concentrations
- High potency with at least 12 billion cfu per capsule at expiry date (guaranteed minimum 18 billion active cells at manufacturing date)
- Includes prebiotic FOS (fructooligosaccharides) inulin to promote probiotic growth
Feature Summary
The microbial ecosystem in the gastrointestinal (GI) tract has emerged as a “virtual organ system”, with growing recognition of its diverse significance in both health maintenance and disease prevention.1 GI microbiota play a critical role in maintaining homeostasis of the innate and cell-mediated immune system and enhance intestinal barrier function through a number of mechanisms, including toxin metabolism, tight junction protein phosphorylation and inflammation reduction.2 Research has clearly shown the importance of intestinal bacteria not just for maintaining optimal gastro-intestinal health, but also for chronic and systemic health conditions such as type 2 diabetes, obesity, and other inflammatory or autoimmune diseases.3-6
Probiotics have multifactorial benefits, by modulating gut immune responses and intestinal barrier functions in a strain and dose-dependent manner. Additionally, mixtures of probiotics appear to have greater efficacy than single strains, perhaps because of synergistic activity or because individuals react differently to various strains.7-10
Probiotic-Pro12 contains 12 bacterial species, each chosen because they can withstand both gastric acid and high-bile concentrations, and for their proven benefits in clinical research, mediated via individual mechanisms of action. The high-quality lactic acid bacteria requires considerable care at all times, therefore over 20 stringent quality control measures are implemented to ensure strain consistency and viability right up until finished product.
Medicinal Ingredients
Each Capsule Contains: | ||
12 billion active cells* of the following specially cultured strains of probiotics: | ||
Total bacterial culture | 12 billion cfu | |
Lactobacillus casei (HA-108) (whole cell) (human) | 25% | 3.00 billion cfu |
Lactobacillus rhamnosus (HA-111) (whole cell) (human) | 12% | 1.44 billion cfu |
Bifidobacterium breve (HA-129) (whole cell) (human) | 10% | 1.20 billion cfu |
Bifidobacterium longum subsp.?longum (HA-135) (whole cell) (human) | 10% | 1.20 billion cfu |
Lactobacillus acidophilus (HA-122) (whole cell) (human) | 10% | 1.20 billion cfu |
Lactobacillus plantarum (HA-119) (whole cell) (plant) | 10% | 1.20 billion cfu |
Lactobacillus rhamnosus (HA-114) (whole cell) (human) | 10% | 1.20 billion cfu |
Bifidobacterium bifidum (HA-132) (whole cell) (human) | 5% | 0.60 billion cfu |
Lactobacillus fermentum (HA-179) (whole cell) (dairy) | 5% | 0.60 billion cfu |
Lactobacillus salivarius (HA-118) (whole cell) (human) | 1% | 0.12 billion cfu |
Lactobacillus paracasei (HA-196) (whole cell) (dairy) | 1% | 0.12 billion cfu |
Bifidobacterium animalis subsp.?lactis (HA-194) (whole cell) (dairy) | 1% | 0.12 billion cfu |
cfu: colony forming units *Guaranteed minimum 12 billion active cells per capsule at expiry date. Guaranteed minimum 18 billion active cells per capsule at manufacture date. |
Non-Medicinal Ingredients
Maltodextrin, vegetarian capsule (carbohydrate gum [cellulose], purified water), fructooligosaccharides (naturally occurring complex fructose molecules derived from beets), inulin (chicory), vegetable grade magnesium stearate (lubricant), silica, ascorbic acid.
Allergens:
Contains no artificial colours, preservatives, or sweeteners; no wheat, gluten, corn, egg, fish, shellfish, salt, tree nuts, or GMOs. Suitable for vegetarians.
Recommended Use:
Recommended Adult Dose: 1–3 capsules per day on a full stomach or as directed by a health care practitioner. Take at least 2–3 hours before or after antibiotics.
Contraindications
Do not use if you have an immune-compromised condition (e.g., AIDS, lymphoma, patients undergoing long-term corticosteroid treatment).
Drug Interactions
No known drug interactions exist. Separation by at least 2 hours from antibiotic use may improve the efficacy of Probiotic-Pro12.
- Evans, J.M., Morris, L.S., Marchesi, J.R. (2013). The gut microbiome: the role of a virtual organ in the endocrinology of the host. J Endocrinol, 218(3), R37-47.
- Ng, S.C., Hart, A.L., Kamm, M.A. (2009). Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis, 15(2), 300-10.
- Ley, R.E., Turnbaugh, P.J., Klein, S., et al. (2006). Microbial ecology: human gut microbes associated with obesity. Nature, 444(7122), 1022-3.
- Othman, M., Agüero, R., Lin, H.C. (2008). Alterations in intestinal microbial flora and human disease. Curr Opin Gastroenterol, 24(1), 11-6.
- Sanz, Y., Moya-Pérez, A. (2014). Microbiota, inflammation and obesity. Adv Exp Med Biol, 817, 291-317.
- Vieira, S.M., Pagovich, O.E., Kriegel, M.A. (2014). Diet, microbiota and autoimmune diseases. Lupus, 23(6), 518-26.
- Williams, E.A., Stimpson, J., Wang, D., et al. (2009). Clinical trial: a multistrain probiotic reparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther, 29(1), 97-103.
- Khalesi, S., Sun, J., Buys, N., Jayasinghe, R. (2014). Effect of Probiotics on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. Hypertension, 64(4), 897-903.
- Chapman, C.M., Gibson, G.R., Rowland, I. (2012). In vitro evaluation of single- and multi-strain probiotics: Inter-species inhibition between probiotic strains, and inhibition of pathogens. Anaerobe, 18(4), 405-13.
- Timmerman, H.M., Koning. C.J., Mulder, L., et al. (2004). Monostrain, multistrain and multispecies probiotics–A comparison of functionality and efficacy. Int J Food Microbiol, 96(3), 219-33.